Pure Global

Blood Glucose Monitoring System - India CDSCO Medical Device Registration

Blood Glucose Monitoring System is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID MFG/MD/2018/000029_0054b22abb292e0ea5155b56e0c4e672_7adb86b5e6718f56594bfca4f6ea992c. This device is marketed under the brand name Merilisa. The license holder is Meril Diagnostics Pvt. Ltd., and it is classified as Device Class Class C. The approving authority is Central Drug Standards Control Organization, Ahmedabad.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class C
Blood Glucose Monitoring System
UID: MFG/MD/2018/000029_0054b22abb292e0ea5155b56e0c4e672_7adb86b5e6718f56594bfca4f6ea992c

Brand Name

Merilisa

Device Class

Class C

Approving Authority

Central Drug Standards Control Organization, Ahmedabad

Product Information

The EXIMO Blood Glucose Monitoring System is advised to be used for the quantitative measurement of glucose (Merilisa) in fresh capillary whole blood. The EXIMO Blood Glucose Monitoring System is intended for use outside the body (Merilisa) by diabetic people at home and by healthcare professionals in a clinical environment; as an aid to monitor the effectiveness of diabetes control. Please note that, it should not be used for the diagnosis of diabetes or for testing newborns

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing